The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

about

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

Item

http://www.wikidata.org/entity/Q37703258

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

@en

The German Lipoprotein Apheresis Registry

@nl

type

Item

label

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

@en

The German Lipoprotein Apheresis Registry

@nl

prefLabel

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

@en

The German Lipoprotein Apheresis Registry

@nl

P1476

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

@en

P2093

A Vogt

http://www.w3.org/2001/XMLSchema#string

C L Neumann

http://www.w3.org/2001/XMLSchema#string

C Peter

http://www.w3.org/2001/XMLSchema#string

E Roeseler

http://www.w3.org/2001/XMLSchema#string

F Heigl

http://www.w3.org/2001/XMLSchema#string

H Blume

http://www.w3.org/2001/XMLSchema#string

P Grützmacher

http://www.w3.org/2001/XMLSchema#string

Scientific Board of GLAR for the German Apheresis Working Group

http://www.w3.org/2001/XMLSchema#string

T Zimmermann

http://www.w3.org/2001/XMLSchema#string

U Julius

http://www.w3.org/2001/XMLSchema#string

P2860

Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

First data from the German Lipoprotein Apheresis Registry (GLAR).

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia.

Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels

Current view: indications for extracorporeal lipid apheresis treatment.

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.

LDL-apheresis: results of longterm treatment and vascular outcome.

Lipoprotein apheresis--more than just cholesterol reduction?

P304

44-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11789-017-0089-9

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28233268

http://www.w3.org/2001/XMLSchema#string

P921

lipoprotein

P932

5352787

http://www.w3.org/2001/XMLSchema#string